ALLO Stock — Allogene Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.69

Market cap

$583.9M

Cash

$332.6M

Enterprise value

$251.3M

Balance sheet

Cash	$332.6M
Debt	$0.0M
Net cash	$332.6M
Enterprise value	$251.3M
Basic shares	345.3M shares
Fully diluted shares	402.3M shares
Fully diluted market cap	$680.0M
Cash per share	$0.96

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ALLO daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	cemacabtagene ansegedleucel	Phase 2	Large B-cell Lymphoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ALLO-316

Phase 1 · Active Modality: AlloCAR T cell therapy

Target CD70

Indications

advanced/metastatic renal cell carcinoma (Stage not disclosed)

Status note Phase 1b research plan completed.

cema-cel

Stage not disclosed · Active Modality: AlloCAR T cell therapy

Aliases cemacabtagene ansegedleucel, ALLO-501A

Target CD19

Indications

large B-cell lymphoma (ALPHA3) (Stage not disclosed)

Status note Filing does not state current phase in 10-Q excerpt.

ALLO-501/UCART19V1

Stage not disclosed · Terminated Modality: AlloCAR T cell therapy

Target CD19

Indications

not disclosed (Stage not disclosed)

Status note Explicitly abandoned in favor of cema-cel; license terminated.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Fludarabine
Lead indication	Large B-cell Lymphoma
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06500273	Phase 2	Recruiting	Sponsor	ALLO	—	Large B-cell Lymphoma	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Allogene Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	22,446,668	+18,650,000	1.02%	2026-08-14
RTW Investments	3,250,000	+3,250,000	0.06%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ALLO — Allogene Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders